| Bioactivity | Salmeterol (GR33343X) is a potent and selective human β2 adrenoceptor agonist. Salmeterol shows potent stimulation of cAMP accumulation in CHO cells expressing human β2, β1 and β3 adrenoceptors with pEC50s of 9.6, 6.1, and 5.9, respectively[1]. | ||||||||||||
| Invitro | Salmeterol (0.001-25 µM) inhibits human T lymphocyte proliferation[2]. Cell Proliferation Assay[2] Cell Line: | ||||||||||||
| In Vivo | Salmeterol (0.16 mg/kg), Formoterol (0.32 mg/kg) and combined treatment have therapeutic effects in mice with chronic obstructive pulmonary disease (COPD)[3]. Animal Model: | ||||||||||||
| Name | Salmeterol | ||||||||||||
| CAS | 89365-50-4 | ||||||||||||
| Formula | C25H37NO4 | ||||||||||||
| Molar Mass | 415.57 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Panayiotis A Procopiou, et al. The discovery of long-acting saligenin β₂ adrenergic receptor agonists incorporating a urea group. Bioorg Med Chem. 2011 Oct 15;19(20):6026-32. [2]. Malcolm Johnson. Effects of beta2-agonists on resident and infiltrating inflammatory cells. J Allergy Clin Immunol. 2002 Dec;110(6 Suppl):S282-90. [3]. Zhiyuan Wang, et al. Efficacy of salmeterol and formoterol combination treatment in mice with chronic obstructive pulmonary disease. Exp Ther Med. 2018 Feb;15(2):1538-1545. |